NCT05883254Not yet recruiting
Pumilio1 (PUM1) Expression, Sickle Cell Anemia, β-thalassemia Intermedia
Detection of RNA Binding Protein Pumilio1 (PUM1) Expression in Patients With Sickle Cell Anemia and β-thalassemia Intermedia
Source: ClinicalTrials.gov · Last updated 31 May 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. To study the expression pattern of PUM1 gene in patients with sickle cell anemia and β-thalassemia intermedia. 2. To detect PUM1 protein levels in sickle cell anemia and β-thalassemia intermedia patients. 3. To correlate PUM1 gene expression pattern and protein levels with HbF levels in sickle cell anemia and β-thalassemia intermedia patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 21 May 2023
- Start date
- 1 Aug 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Assiut University
- Diseases
- Sickle cell disease, Thalassaemia
- NCT number
- NCT05883254
What you commit to
- Study type: Observational
- Planned participants: 80
- From 1 Aug 2023 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients on Hydroxyurea therapy.
Other
- Patients with any other type of haemolytic anaemias.
Who the study is looking for
- Patients with sickle cell anemia and β-thalassemia intermedia.
- Patients are of both sexes (males and females) at any age.
Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.